Last reviewed · How we verify
Neodyne (ETHYL DIBUNATE)
Neodyne (generic name: ETHYL DIBUNATE) is a drug. It is currently in Phase 2 development.
Neodyne works by binding to specific proteins or receptors in the body, altering their function and leading to a therapeutic effect.
Neodyne Biosciences, Inc. is conducting a study on a novel silicone dressing, known as the Neodyne Device, to minimize scar formation. The study is focused on conditions such as hypertrophic scars, cicatrix, and breast reconstruction.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETHYL DIBUNATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a orchestra, and the proteins or receptors are like the musicians. Neodyne is like a conductor that helps the musicians play in harmony, leading to a desired outcome. However, if the conductor is too loud or too soft, it can cause problems, and that's where the safety considerations come in.
Approved indications
Common side effects
Key clinical trials
- Abdominal Scar Improvement in Microsurgical Breast Reconstruction (NA)
- Investigation of a Novel Mechanomodulating Polymer to Maximize the Outcomes of Scar Revision Procedures (NA)
- Scar Prevention and the Clinical Effectiveness of a Novel Mechanomodulating Polymer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neodyne CI brief — competitive landscape report
- Neodyne updates RSS · CI watch RSS
Frequently asked questions about Neodyne
What is Neodyne?
How does Neodyne work?
What is the generic name of Neodyne?
What development phase is Neodyne in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing